middle.news
How Prescient’s $9.85M Raise Fuels PTX-100’s Fight Against Rare Lymphoma
6:20pm on Tuesday 24th of February, 2026 AEDT
•
Healthcare
Read Story
How Prescient’s $9.85M Raise Fuels PTX-100’s Fight Against Rare Lymphoma
6:20pm on Tuesday 24th of February, 2026 AEDT
Key Points
62.8% increase in half-year loss to $3.99 million
Raised $9.85 million via Placement and Share Purchase Plan
Positive Phase 1b PTX-100 data with 43% response rate in CTCL patients
EMA grants Orphan Drug Designation and CTIS trial approval for PTX-100
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
PRESCIENT THERAPEUTICS (ASX:PTX)
OPEN ARTICLE